- Bora Pharmaceuticals is leveraging the Groninger® FlexPro 50 Isolator Line to enhance aseptic fill/finish production for vials and pre-filled syringes.
- The company has partnered with Accord BioPharma to manufacture pre-filled syringes of UDENYCA® (pegfilgrastim-cbqv) at its Baltimore site.
Bora Pharmaceuticals Co., Ltd. has announced the use of its Groninger® FlexPro 50 Isolator Line for vials and pre-filled syringes to expand access to lifesaving treatments and therapies.
The company, a global CDMO, is integrating advanced isolator technology into its aseptic fill/finish operations to strengthen its contract manufacturing capabilities. The Baltimore facility will play a central role in scaling production and meeting growing market needs.
Bora has partnered with Accord BioPharma, Inc. to produce pre-filled syringes of UDENYCA® (pegfilgrastim-cbqv), a therapy used to support immune health in cancer care. The new isolator line will enable large-scale manufacturing to help meet patient demand across the United States.
“We’re excited to combine Bora’s manufacturing expertise with Accord’s desire to increase production to meet demand and manufacture in the United States. Our team’s deep technical knowledge will play a vital role in accomplishing these goals.”
David Fidler, Vice President and General Manager of Bora Pharmaceuticals Baltimore
